FR2877572A1 - Pharmaceutical composition for oral administration or of functional food, used to prevent or treat acne, contains lycopene and chlorogenic acid - Google Patents

Pharmaceutical composition for oral administration or of functional food, used to prevent or treat acne, contains lycopene and chlorogenic acid Download PDF

Info

Publication number
FR2877572A1
FR2877572A1 FR0412055A FR0412055A FR2877572A1 FR 2877572 A1 FR2877572 A1 FR 2877572A1 FR 0412055 A FR0412055 A FR 0412055A FR 0412055 A FR0412055 A FR 0412055A FR 2877572 A1 FR2877572 A1 FR 2877572A1
Authority
FR
France
Prior art keywords
chlorogenic acid
acne
lycopene
prevent
functional food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR0412055A
Other languages
French (fr)
Other versions
FR2877572B1 (en
Inventor
Claude Bonne
Daniel Sincholle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR0412055A priority Critical patent/FR2877572B1/en
Publication of FR2877572A1 publication Critical patent/FR2877572A1/en
Application granted granted Critical
Publication of FR2877572B1 publication Critical patent/FR2877572B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pharmaceutical composition (I) for oral administration or of functional food, to prevent and treat acne, contains lycopene (5-25 mg) and chlorogenic acid (10-100 mg). An independent claim is also included for a dermo-cosmetologic composition, to prevent or treat acne, comprising (I) ( 0.5-5%). ACTIVITY : Antiseborrheic; Dermatological. MECHANISM OF ACTION : None given.

Description

La présente invention concerne des compositions pharmaceutiques,The present invention relates to pharmaceutical compositions,

cosmétiques ou alimentaires contenant une association de lycopène et d'acide chlorogénique, destinée à réduire les lésions acnéiques. Cette approche du traitement de l'acné par une composition pharmaceutique, cosmétique ou alimentaire apportant du  cosmetics or food containing a combination of lycopene and chlorogenic acid, intended to reduce acne lesions. This approach to the treatment of acne with a pharmaceutical, cosmetic or food composition providing

S lycopène constitue une démarche originale par le fait que le lycopène est un caroténoïde non précurseur du rétinol. Par ailleurs l'invention est fondée sur l'association du lycopène et de l'acide chlorogénique dont les mécanismes d'action sont complémentaires et synergiques.  S lycopene is an original approach in that lycopene is a carotenoid non-precursor of retinol. Moreover, the invention is based on the combination of lycopene and chlorogenic acid whose mechanisms of action are complementary and synergistic.

L'acné est une affection très fréquente qui se manifeste par les lésions cutanées - a que sont les comédons et les papulo-pustules. Ces lésions peuvent être améliorées par des médicaments topiques comme l'acide rétinoïque, kératolytique, ou systémiques comme l'isotrétinoïne qui provoque l'involution des glandes sébacées, ou bien encore par des soins cosmétiques locaux.  Acne is a very common condition that is manifested by skin lesions - what are comedones and papulopustules. These lesions can be improved by topical medications such as retinoic acid, keratolytic acid, or systemic drugs such as isotretinoin, which causes involution of the sebaceous glands, or by local cosmetics.

Trois événements interviennent dans la pathogénie de l'acné au niveau du ç follicule pilo-sébacé: 1) la production augmentée de sébum par les glandes sébacées sous l'action des hormones androgènes, 2) l'anomalie de la kératinisation infundibulaire conduisant à l'obstruction du canal et à la rétention du matériel folliculaire formant microkystes et comédons, 3) la prolifération folliculaire de Propionibacterium acnes stimulant la diapédèse leucocytaire dont résulte lla formation de papulo-pustules.  Three events are involved in the pathogenesis of acne in the pilosebaceous follicle: 1) increased production of sebum by the sebaceous glands under the action of androgenic hormones, 2) abnormality of infundibular keratinization leading to obstruction of the canal and retention of follicular material forming microcysts and comedones, 3) follicular proliferation of Propionibacterium acnes stimulating leucocyte diapedesis resulting in the formation of papulopustules.

Lo Les auteurs se fondant sur l'observation selon laquelle le lycopène et l'acide chlorogénique sont capables d'interagir ensemble à ces différents niveaux, ont défini la présente invention.  The authors, based on the observation that lycopene and chlorogenic acid are capable of interacting together at these different levels, have defined the present invention.

La pathogénie de l'acné commence par une hyperplasie des glandes holocrines qui forment le sébum, les glandes sébacées. La séborrhée est reconnue comme un ts" facteur nécessaire au développement des lésions acnéiques, tant kystiques qu'inflammatoires. De même que les glandes sexuelles annexes comme la prostate, les glandes sébacées contiennent des récepteurs des hormones androgènes et leur croissance est strictement androgéno-dépendante. Ainsi des médicaments antiandrogèniques administrés par voie orale, comme des antagonistes hormonaux (cyprotérone) et des inhibiteurs de la 5-alpha-réductase (finastéride), ont -ils été proposés pour traiter l'acné. Le lycopène suscite un très grand intérêt en raison de son effet protecteur vis à vis du cancer de la prostate, effet démontré par plusieurs études épidémiologiques. Son mécanisme d'action semble multiple. Comme les autres caroténoïdes, il présente une puissante activité antioxydante qui pourrait rendre compte de son effet anticancéreux, toutefois le fait qu'il est aussi capable d'inhiber la croissance de l'épithélium prostatique sain et de réduire l'expression de la 5-alpha-réductase suggère que l'un de ses mécanismes d'action est un effet anti-androgène. L'analogie entre la prostate et la glande sébacée a donc amené les auteurs à considérer l'intérêt du lycopène dans le traitement de la séborrhée et par conséquent de l'acné.  The pathogenesis of acne begins with hyperplasia of the holocrine glands that form sebum, the sebaceous glands. Seborrhea is recognized as a "necessary factor in the development of acne lesions, both cystic and inflammatory.As with the accessory sex glands such as the prostate, the sebaceous glands contain androgen receptors and their growth is strictly androgen-dependent For example, oral anti-androgenic drugs such as hormonal antagonists (cyproterone) and 5-alpha-reductase inhibitors (finasteride) have been proposed to treat acne, and lycopene is of great interest. because of its protective effect against prostate cancer, an effect demonstrated by several epidemiological studies.Its mechanism of action seems multiple.As other carotenoids, it has a powerful antioxidant activity that could account for its anticancer effect, however the fact that it is also able to inhibit the growth of the epithelium healthy prostate and reduce the expression of 5-alpha-reductase suggests that one of its mechanisms of action is an anti-androgenic effect. The analogy between the prostate and the sebaceous gland has led the authors to consider the interest of lycopene in the treatment of seborrhea and therefore acne.

Des études récentes se sont attachées à mesurer la production des espèces oxygénées réactives (EOR) et l'activité des défenses antioxydantes chez les patients to acnéiques. Ainsi il a été montré que les leucocytes des patients présentant des lésions inflammatoires génèrent plus de peroxyde d'hydrogène lors de la phagocytose que ceux des sujets sains. Il a aussi été montré que les activités superoxyde dismutase et glutathion peroxydase étaient diminuées chez les patients présentant des papulopustules acnéiques. Ces résultats suggèrent qu'un déficit des défenses antioxydantes i pourrait participer au développement des lésions inflammatoires de l'acné. Enfin, ces données trouvent un écho dans le fait que le tabagisme, reconnu pour diminuer les défenses antioxydantes, est considéré comme un facteur de risque de l'acné . Les EOR générées par les macrophages et les polynucléaires sont des facteurs centraux des réactions inflammatoires notamment parcequ'elles stimulent Y.o l'expression d' intégrines et de cytokines comme l'interleukine 1 (IL-1) et l'IL-8, cytokines chimiotactiques pour les polynucléaires neutrophiles. Par ailleurs, ces cytokines pourraient intervenir aussi dans la formation des comédons, lésions primaires de la maladie puisqu'elles sont déjà surexprimées autour des microcomédons, lésions infracliniques qui ne présentent qu'une hyperprolifération de l'épithélium folliculaire. II ZS" apparaît donc que les EOR, initiatrices de l'expression de cytokines et de la réaction inflammatoire, seraient impliquées aux stades les plus précoces de la pathogénie de l'acné.  Recent studies have focused on measuring the production of reactive oxygen species (ROS) and the activity of antioxidant defenses in patients to acne. Thus, it has been shown that leukocytes in patients with inflammatory lesions generate more hydrogen peroxide during phagocytosis than those in healthy subjects. It has also been shown that superoxide dismutase and glutathione peroxidase activities are decreased in patients with acne papulopustules. These results suggest that a deficiency of antioxidant defenses i could participate in the development of inflammatory lesions of acne. Finally, these data are echoed by the fact that smoking, known to decrease antioxidant defenses, is considered a risk factor for acne. EORs generated by macrophages and polynuclear cells are central factors in inflammatory reactions, particularly because they stimulate the expression of integrins and cytokines such as interleukin-1 (IL-1) and IL-8, chemotactic cytokines. for neutrophils. Moreover, these cytokines could also be involved in the formation of comedones, the primary lesions of the disease since they are already overexpressed around microcomedons, subclinical lesions that present only a hyperproliferation of the follicular epithelium. It is therefore apparent that EORs, initiators of cytokine expression and inflammatory response, would be involved in the earliest stages of the pathogenesis of acne.

La présente invention consiste donc en des compositions contenant des antioxydants, le lycopène qui agit par ailleurs comme anti-androgène et l'acide 2, chlorogénique, constituant dont les auteurs ont démontré l'activité inhibitrice du chimiotactisme des leucocytes et qui présente une activité anti-bactérienne.  The present invention therefore consists of compositions containing antioxidants, lycopene which also acts as an anti-androgen and 2, chlorogenic acid, constituent whose authors have demonstrated the inhibitory activity of leukocyte chemotaxis and which has an anti-inflammatory activity. -bactérienne.

La présente invention consiste donc en des préparations pharmaceutiques, cosmétiques ou d'aliments fonctionnels contenant une association de lycopène et d'acide chlorogénique pour la prévention et le traitement de l'acné, capable de s'opposer à la séborrhée, facteur étiologique de l'acné, ainsi qu'à la cornédogénèse et la formation des papulo-pustules acnéiques.  The present invention therefore consists of pharmaceutical, cosmetic or functional food preparations containing a combination of lycopene and chlorogenic acid for the prevention and treatment of acne, capable of opposing seborrhea, a causal factor of the disease. acne, as well as the cornedogenesis and formation of acne papulo-pustules.

Le lycopène peut être apporté sous toutes formes comme un extrait, une oléorésine ou une poudre de tomate déshydratée. De même, l'acide chlorogénique peut être apporté sous toutes formes comme un extrait d'artichaut ou de café.  Lycopene can be provided in any form such as an extract, an oleoresin or dehydrated tomato powder. Similarly, chlorogenic acid can be provided in any form such as an artichoke or coffee extract.

Les compositions pharmaceutiques, cosmétiques ou alimentaires selon l'invention peuvent contenir éventuellement toutes les substances connues pour leurs (o propriétés bénéfiques dans l'acné comme par exemple les sels de zinc ou d'autres substances antioxydants et anti-inflammatoires. Les compositions selon l'invention peuvent se présenter sous toutes les formes solides ou liquides utilisées en pharmacie, diététique ou alimentation fonctionnelle, telles que gélules, capsules huileuses, comprimés, sachets, poudres, barres, biscuits, solutions en ampoules, flacons, ou être tç mélangés à des aliments plus traditionnels tels que yaourts, et des boissons. Pour les applications topiques, les compositions selon l'invention peuvent se présenter sous toutes les formes utilisées en cosmétique telles que crèmes, lotions et gels. Elles sont obtenues selon les méthodes utilisées dans ces domaines.  The pharmaceutical, cosmetic or food compositions according to the invention may optionally contain all the substances known for their beneficial properties in acne, for example zinc salts or other antioxidant and anti-inflammatory substances. The invention may be in any solid or liquid form used in pharmacy, dietetics or functional food, such as capsules, oily capsules, tablets, sachets, powders, bars, cookies, solutions in ampoules, flasks, or mixtures thereof. More traditional foods such as yogurts, and beverages For topical applications, the compositions according to the invention can be in any form used in cosmetics such as creams, lotions and gels.They are obtained according to the methods used in these fields. .

Dans les préparations à usage interne, la dose de lycopène est comprise entre 5 et 25 mg et celle d'acide chlorogénique entre 10 et 100 mg. Dans les préparations à usage local, les concentrations de lycopène et d'acide chlorogénique sont comprises entre 0,5 et 5 0/0.  In preparations for internal use, the dose of lycopene is between 5 and 25 mg and that of chlorogenic acid between 10 and 100 mg. In the preparations for local use, the concentrations of lycopene and chlorogenic acid are between 0.5 and 50%.

Exemples de compositions Exemple 1- gélules ou comprimés: g Lycopène 10 mg Acide chlorogénique 20 mg Excipient QSP 1 gélule ou 1 comprimé de 500 rng Exemple 2- capsules: Oléorésine de tomate à 5% de lycopène 100 mg Extrait de café à 5% d'acide chlorogénique 100 mg Excipient QSP 1 capsule de 300 mg 4 Exemple 3- Solution buvable: Extrait de tomate à 10/0 de lycopène 500 mg Vitamine C 100 mg Acide chlorogénique 50 mg S Excipient QSP 10 ml Exemple 4- crème dermique: Lycopène 100 mg Acide chlorogénique 200 mg Excipient QSP 10 g s  EXAMPLES OF COMPOSITIONS EXAMPLE 1 Capsules or Tablets Lycopene 10 mg Chlorogenic acid 20 mg QSP excipient 1 capsule or 500 rng tablet Example 2 capsules: Lycopene 5% tomato oleoresin 100 mg 5% coffee extract Chlorogenic acid 100 mg Excipient QSP 1 capsule 300 mg 4 Example 3- Oral solution: Tomato extract 10% Lycopene 500 mg Vitamin C 100 mg Chlorogenic acid 50 mg S Excipient QSP 10 ml Example 4 Skin cream: Lycopene 100 mg Chlorogenic Acid 200 mg Excipient QSP 10 gs

Claims (2)

REVENDICATIONS 1-Composition pharmaceutique pour la voie orale ou d'aliment fonctionnel destinée à la prévention et au traitement de l'acné caractérisée en ce qu'elle contient du lycopène (5 à 25 mg / unité de prise) et de l'acide chlorogénique (10 à 100 mg/ unité de prise).  Pharmaceutical composition for the oral route or functional food intended for the prevention and treatment of acne, characterized in that it contains lycopene (5 to 25 mg / dose unit) and chlorogenic acid ( 10 to 100 mg / unit dose). 2-Composition dermocosmétologique destinée à la prévention et au traitement de l'acné caractérisée en ce qu'elle contient du lycopène et de l'acide chlorogénique à des concentrations comprises entre 0,5 et 5 %.2-dermocosmetological composition for the prevention and treatment of acne characterized in that it contains lycopene and chlorogenic acid at concentrations between 0.5 and 5%.
FR0412055A 2004-11-10 2004-11-10 NOVEL PHARMACEUTICAL, FOOD OR COSMETIC COMPOSITIONS FOR PREVENTING AND TREATING ACNE Expired - Fee Related FR2877572B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0412055A FR2877572B1 (en) 2004-11-10 2004-11-10 NOVEL PHARMACEUTICAL, FOOD OR COSMETIC COMPOSITIONS FOR PREVENTING AND TREATING ACNE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0412055A FR2877572B1 (en) 2004-11-10 2004-11-10 NOVEL PHARMACEUTICAL, FOOD OR COSMETIC COMPOSITIONS FOR PREVENTING AND TREATING ACNE

Publications (2)

Publication Number Publication Date
FR2877572A1 true FR2877572A1 (en) 2006-05-12
FR2877572B1 FR2877572B1 (en) 2008-03-21

Family

ID=34951948

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0412055A Expired - Fee Related FR2877572B1 (en) 2004-11-10 2004-11-10 NOVEL PHARMACEUTICAL, FOOD OR COSMETIC COMPOSITIONS FOR PREVENTING AND TREATING ACNE

Country Status (1)

Country Link
FR (1) FR2877572B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019197788A1 (en) * 2018-04-13 2019-10-17 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Use of a novel composition for preventing or slowing down the appearance of unsightly signs relating to the presence of excess sebum

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03188019A (en) * 1989-12-15 1991-08-16 Shiseido Co Ltd Testosterone-5alpha-reductase inhibitor
WO2002094210A2 (en) * 2001-05-21 2002-11-28 Cognis France S.A. Cosmetic agents
FR2838056A1 (en) * 2002-04-08 2003-10-10 Oreal Promoting endogenous superoxide dismutase production, using extract of non-photosynthetic, non-fruiting filamentous bacteria, useful in cosmetic or dermatological applications, e.g. for combating skin aging
WO2004052351A1 (en) * 2002-12-06 2004-06-24 Dsm Ip Assets B.V. Novel use of lycopene
US20040156873A1 (en) * 2003-02-10 2004-08-12 Gupta Shyam K. Topically Bioavailable Acne and Rosacea Treatment Compositions
FR2853246A1 (en) * 2003-04-03 2004-10-08 Claude Bonne Pharmaceutical or food composition, useful for the treatment or prevention of inflammation, especially acne, contains alcoholic polyphenol containing extract of sunflower seeds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03188019A (en) * 1989-12-15 1991-08-16 Shiseido Co Ltd Testosterone-5alpha-reductase inhibitor
WO2002094210A2 (en) * 2001-05-21 2002-11-28 Cognis France S.A. Cosmetic agents
FR2838056A1 (en) * 2002-04-08 2003-10-10 Oreal Promoting endogenous superoxide dismutase production, using extract of non-photosynthetic, non-fruiting filamentous bacteria, useful in cosmetic or dermatological applications, e.g. for combating skin aging
WO2004052351A1 (en) * 2002-12-06 2004-06-24 Dsm Ip Assets B.V. Novel use of lycopene
US20040156873A1 (en) * 2003-02-10 2004-08-12 Gupta Shyam K. Topically Bioavailable Acne and Rosacea Treatment Compositions
FR2853246A1 (en) * 2003-04-03 2004-10-08 Claude Bonne Pharmaceutical or food composition, useful for the treatment or prevention of inflammation, especially acne, contains alcoholic polyphenol containing extract of sunflower seeds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 015, no. 440 (C - 0883) 11 November 1991 (1991-11-11) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019197788A1 (en) * 2018-04-13 2019-10-17 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Use of a novel composition for preventing or slowing down the appearance of unsightly signs relating to the presence of excess sebum
FR3080030A1 (en) * 2018-04-13 2019-10-18 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic USE OF A NEW COMPOSITION FOR PREVENTING OR SLOWING THE APPEARANCE OF INESTHETIC SIGNS RELATED TO THE PRESENCE OF SEBUM IN EXCESS

Also Published As

Publication number Publication date
FR2877572B1 (en) 2008-03-21

Similar Documents

Publication Publication Date Title
Li et al. Retinal accumulation of zeaxanthin, lutein, and β-carotene in mice deficient in carotenoid cleavage enzymes
EP1515712B1 (en) Use of taurine for the treatment of alopecia
JP6687806B2 (en) Coenzyme Q10 solubilizing composition and method for producing the same
FR2969495A1 (en) EXTRACT OF MACA-RICH AERIAL PARTS OF POLYPHENOLS AND COMPOSITION COMPRISING THE SAME
KR20090003354A (en) Water-soluble pharmaceutical compositions of hops resins
FR2980691A1 (en) WASHING COMPOSITION
WO2006131653A1 (en) Composition based on an avermectine and metronidazole in particular for treating rosacea
EP1890773A1 (en) Use of a griffonia extract, in particular griffonia simplicifolia, in a cosmetic or dermatological composition for mitigating pigmentation of skin and skin appendages
FR2969494A1 (en) EXTRACT OF AIR PARTS OF GYNANDROPSIS GYNANDRA OR CLEOME GYNANDRA AND COSMETIC, DERMATOLOGICAL COMPOSITIONS COMPRISING SAME
KR20200095476A (en) Dietary composition containing a plant-based fatty acid source
WO2006131652A1 (en) Composition based on an avermectine and benzoyl peroxide in particular for treating rosacea
Islam et al. Targeted therapies of curcumin focus on its therapeutic benefits in cancers and human health: Molecular signaling pathway-based approaches and future perspectives
US8668942B2 (en) Skin anti-oxidant enhancing formulation and associated method
FR2816843A1 (en) 5-Alpha reductase inhibitor used for treating disorders due to excess dihydrotestosterone e.g. acne and alopecia comprise cis or trans resveratrol and its derivatives
WO2006131651A2 (en) Avermectin and hydrocortisone-based composition, in particular for roracea treatment
FR2877572A1 (en) Pharmaceutical composition for oral administration or of functional food, used to prevent or treat acne, contains lycopene and chlorogenic acid
CA3042592A1 (en) Inteligent delivery of ingested and absorbed molecules
JP2007197360A (en) Melanogenesis inhibitor, active oxygen scavenger and composition containing the scavenger
Ghaeini Hesarooeyeh et al. Effect of resveratrol and curcumin and the potential synergism on hypertension: A mini‐review of human and animal model studies
KR20070000675A (en) Composition containing mung bean extract, bletillae tuber extract and black cohosh extract and use thereof
de Castilho et al. Boswellia serrata
EP3242674B1 (en) Compositions containing curcumin having improved bioavailability
CA2850685C (en) Process for producing fucoxanthinol extract and methods of use
FR2845900A1 (en) Cosmetic composition useful for e.g. preventing and/or correcting the functional disorders of pilosebaceous unit of mammals comprises polyunsaturated fatty acid, flavonoid and stilbene
FR2841101A1 (en) Oral administration of taurine and hypotaurine for the prevention and treatment of hair loss

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20090731